ONdrugDelivery | Global Drug Delivery Industry Information & Intelligence

CGT

PRIMARY PACKAGING AND ADMINISTRATION OF CELL THERAPIES: CURRENT TRENDS AND CHALLENGES

Dr Krishnendu Khan and Henry Nguyen of West Pharmaceutical Services examine factors to consider when designing and selecting primary packaging for cell therapies, exploring the effects of cryogenic storage on packaging and cells, while highlighting the diverse delivery methods and applications for these therapies.

EVOLVING ELASTOMER STOPPER TECHNOLOGIES FOR A CHANGING REGULATORY LANDSCAPE

Dr Laure-Hélène Guillemot and Edouard Pagnoud assess the impact of the per- and polyfluoroalkyl substances ban on elastomer stoppers and the resulting extractables and leachables challenges, highlighting how Aptar Pharma is developing new solutions to meet both regulatory expectations and customer needs.

THE IMPORTANCE OF MESH NEBULISER CONFIGURATION IN mRNA-LNP DELIVERY PERFORMANCE

Hanna Beike and Dr Benjamin Heine highlight the superior performance of customisable drug-specific nebuliser platforms, such as eFlowM^® Open System and eFlow^® Integrated, for the delivery of messenger RNA-based inhalation therapies.

USING OXYCAPT™ MULTILAYER PLASTIC VIAL FOR GENE AND CELL THERAPIES STORED IN DRY ICE AND LIQUID NITROGEN

PREFILLED SYRINGES

Hiroki Hasegawa

Mitsubishi Gas Chemical

USING OXYCAPT™ MULTILAYER PLASTIC VIAL FOR GENE AND CELL THERAPIES STORED IN DRY ICE AND LIQUID NITROGEN

Hiroki Hasegawa and Tomohiro Suzuki consider the various challenges presented by cold-chain logistics to both traditional glass vials and many cyclo-olefin polymer alternatives, and how Mitsubishi Gas Chemical's OXYCAPT™ vials offer significant advantages for maintaining container closure integrity compared with other materials on the market.

IMPROVING RNA THERAPEUTIC TARGETING BEYOND DELIVERY

Dr Fiona McLaughlin

IMPROVING RNA THERAPEUTIC TARGETING BEYOND DELIVERY

Dr Fiona McLaughlin and Dr Mark Edbrooke discuss the possibilities for developing novel cancer treatments using functionalised nanoparticles, in order to transport a variety of therapies into the tumour microenvironment.

REVEALING THE FRONTIER: DRUG DELIVERY CHALLENGES AND INNOVATIONS IN OCULAR GENE THERAPY

Dr Max Chambers

REVEALING THE FRONTIER: DRUG DELIVERY CHALLENGES AND INNOVATIONS IN OCULAR GENE THERAPY

Dr Max Chambers discusses novel approaches for delivering ocular gene therapies, summarising the challenges and benefits of various delivery routes and exploring the devices used to successfully improve vision.

PRECISION DELIVERY: SEAMLESS COLLABORATION FOR DELIVERING NEURO-THERAPEUTICS

Professor Steven Gill

PRECISION DELIVERY: SEAMLESS COLLABORATION FOR DELIVERING NEURO-THERAPEUTICS

Professor Steven Gill and Alan Suttie provide insight into the unique collaboration and design philosophy behind their novel scalable interventional delivery system for gene and cell therapies – the Neurochase Acute Drug Delivery System.

DRUG DELIVERY IN CELL AND GENE THERAPY: WHY EARLY DEVICE DEVELOPMENT MATTERS

DRUG DELIVERY IN CELL AND GENE THERAPY: WHY EARLY DEVICE DEVELOPMENT MATTERS

Bharat Arora discusses how the delivery method for a cell and gene therapy is an integral part of the overall product, inextricable from the therapy itself, and how properly synchronising drug and delivery device development can greatly benefit the overall development programme.

CELL AND GENE THERAPY DIGITAL INFRASTRUCTURE: REPLACING FRAGMENTATION WITH STANDARDISATION

CELL AND GENE THERAPY DIGITAL INFRASTRUCTURE: REPLACING FRAGMENTATION WITH STANDARDISATION

Dr Akshay Peer examines why bespoke digital systems for cell and gene therapies are reaching a saturation point, how clinicians experience this fragmentation on the ground and why a shift towards standardisation is becoming essential for enabling safe, scalable and sustainable delivery of these innovative treatments.

MAPPING INNOVATION IN mRNA DELIVERY THROUGH PATENT TRENDS

Dr Elodie Bovier

MAPPING INNOVATION IN mRNA DELIVERY THROUGH PATENT TRENDS

Dr Elodie Bovier considers the evolution of messenger RNA therapeutics in biotechnology, examining patent trends and exploring how they have triggered litigation in the field, demonstrating the growth and maturity of this sector.

SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION

Dr Ethan Miller

SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION

Dr Ethan Miller examines the manufacturing of cell and gene therapies where shear stress can impact cells and explores strategies to mitigate such damage, helping to ensure that therapies retain their viability, functionality and therapeutic potency from production through to administration.

PRECISION DELIVERY: THE MISSING LINK IN CELL & GENE THERAPY

Jessica Alzamora

PRECISION DELIVERY: THE MISSING LINK IN CELL & GENE THERAPY

Jessica Alzamora, Dr Karla Sanchez and Emily Chang discuss the necessity for precision when delivering cell and gene therapies, explore how this precision can be designed and demonstrated, then go on to describe how a minimum viable product approach to device development can act as a strong predictor of a successful delivery device.

DRUG DELIVERY DEVICE INNOVATION IN CELL AND GENE THERAPIES

Alejandra Sanchez

DRUG DELIVERY DEVICE INNOVATION IN CELL AND GENE THERAPIES

Dr Alejandra Sanchez and Charlie Dean consider the evolution of drug delivery technologies and how cell and gene therapies are showing promise as a new class of medicine to correct disease at its source.

21st Jan 2026 - 22nd Jan 2026

Paris, France

Launched in 1997, Pharmapack is the leading European event for Pharmaceutical Packaging, Drug Delivery, Medical Devices and Machinery. Over the past 25+ years, it has grown from a small conference to a major international event with >6,000 attendees, >65 content sessions, and >400 exhibitors from more than 90 countries.

CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT

Catalent Pharma Solutions

CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT

Carolyn Berg and Dr Alan Watts examine strategy considerations that can help emerging biotech companies navigate early-stage pulmonary drug development, providing practical guidance for addressing challenges of respiratory delivery and avoiding common pitfalls that can derail development programmes.

Interview: Aptar Pharma Expansion With New R&D Center

Christophe Pierre

Interview: Aptar Pharma Expansion With New R&D Center

In this interview, Christophe Pierre introduces Aptar Pharma’s new R&D Center in France, and outlines how the new facility will assist the development of smarter, more integrated drug delivery solutions, facilitating progression from concept to full-scale industrialisation across multiple therapeutic fields.

RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?

RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?

Mark Parry discusses the potential needs and opportunities for respiratory drug delivery devices in the context of a hypothetical global vaccination strategy, considering a variety of factors and how different respiratory device approaches could perform.

STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER

Dr Yannick Baschung

STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER

Dr Yannick Baschung discusses the benefits and challenges of orally inhaled and nasal drug products and examines how drug developers can stress test their products to improve regulatory success and patient safety, as well as how partnering with an expert CRO can provide an efficient way of performing critical characterisation testing.

DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL

DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL

As dissolution testing rises up the agenda for orally inhaled product developers, Jamie Clayton explores drivers behind its adoption and key considerations for developing a robust and relevant method.

INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES

Dr Philippe Rogueda

INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES

Dr Philippe Rogueda discusses the therapeutic potential promised by oligonucleotides and presents the case for prioritising the inhalation route as the ideal delivery mechanism for these drugs, highlighting how direct delivery to the lungs via devices such as dry power inhalers or soft mist inhalers can maximise the therapeutic efficacy and minimise the side effects of these exciting drugs.

HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES

Dr Peter Harley

HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES

Dr Peter Harley, Mariam Al-Amari and Matt Jones explore how in silico approaches can transform pulmonary and nasal drug delivery device development, illustrating through case studies – spanning low-global-warming potential propellants, assembly robustness, device-user interaction, variability and capsule piercing dynamics – how simulation-led in silico approaches can improve understanding of device performance and identify risks early, reducing development costs and accelerating the path to more reliable, innovative and patient-friendly drug-device systems.

DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE

DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE

Chris Gilmor considers the issues affecting dry powder inhalers and explains how formulators use a range of techniques to ensure dose dispersion and API detachment. He goes on to explain the importance of controlling the moisture level in these devices and how it can affect the drug delivery performance of the formulation.

CLEARING THE AIR(WAY): DEBUNKING THREE COMMON MYTHS ABOUT INHALED DRUG DELIVERY

Dr Keat Theng Chow

CLEARING THE AIR(WAY): DEBUNKING THREE COMMON MYTHS ABOUT INHALED DRUG DELIVERY

Dr Keat Theng Chow and Susana Ecenarro explore three myths surrounding inhalation as a route of administration, clearing the way for a deeper understanding of one of pharma’s most exciting areas for innovation.

FAST-TO-MARKET DEVELOPMENT OF A NOVEL NASAL SPRAY WITH SIMULTANEOUS ENGINEERING

Matthias Müller

FAST-TO-MARKET DEVELOPMENT OF A NOVEL NASAL SPRAY WITH SIMULTANEOUS ENGINEERING

Matthias Müller details how a close collaboration between Contexo and a pharmaceutical manufacturer led to the rapid development of a novel nasal spray product, taking the project from prototyping to market within 14 months, shaving 10 months off the anticipated launch date.

Interview: Integrating Phillips Medisize and Vectura’s Operations

Charlie Schumacher

Phillips Medisize

Interview: Integrating Phillips Medisize and Vectura’s Operations

In this interview, Charlie Schumacher and Sandy Munro discuss Phillips Medisize’s progress on its integration of Vectura, covering aspects such as cultural alignment, technical innovation and the evolving role of CDMOs in the inhalation landscape.

ADVANCING ELASTOMER SEAL SOLUTIONS FOR THE PRESSURISED METERED DOSE INHALER MARKET

INDUSTRIALISATION

Parker O-Ring & Engineered Seals Division

ADVANCING ELASTOMER SEAL SOLUTIONS FOR THE PRESSURISED METERED DOSE INHALER MARKET

Nathan Sowder discusses Parker O-Ring & Engineered Seals Division’s role and history in providing advanced elastomer seals and components to the drug delivery industry, with a particular emphasis on pressurised metered dose inhalers.

FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT

FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT

Ross Errington introduces Bespak’s Holmes Chapel (UK) site, which is equipped to support device development programmes from early-stage formulation to large-scale manufacture.

1
2
3
…
69
Next

See what ondrugdelivery's readers and contributors think

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Top